

1 **Integrative Hospital Treatment in Older patients to benchmark**  
2 **and improve Outcome and Length of stay – the *In-HospitoOL***  
3 **study**

4 *A quasi-experimental, multicenter comparative effectiveness trial*  
5 *study protocol*

6  
7 *Protocol version V1.1 (13.10.2016)*

8  
9 **Principal Investigator and correspondence:**

10 Prof. Dr. med. Beat Mueller, M.D.  
11 Department of Internal Medicine  
12 Department of Endocrinology, Diabetes and Clinical Nutrition  
13 University Department of Internal Medicine,  
14 Kantonsspital Aarau, Tellstrasse, CH-5001 Aarau, Switzerland  
15 Email: [happy.mueller@unibas.ch](mailto:happy.mueller@unibas.ch)  
16

17  
18 **Collaborations & research network**

19 <sup>1</sup>Alexander Kutz, MD; <sup>1</sup>Daniel Koch; <sup>1</sup>Antoinette Conca; <sup>1</sup>Ciril Baechli; <sup>1</sup>Sebastian  
20 Haubitz; <sup>1</sup>Katharina Regez; <sup>1</sup>Ursula Schild; <sup>1</sup>Zeljka Caldara; <sup>2</sup>Fahim Ebrahimi, MD;  
21 <sup>2</sup>Stefano Bassetti, MD; <sup>2</sup>Jens Eckstein, MD PhD; <sup>3</sup>Juerg Beer, MD; <sup>3</sup>Michael Egloff,  
22 MD; <sup>4</sup>Vladimir Kaplan, MD; <sup>5</sup>Tobias Ehmann, MD; <sup>6</sup>Claus Hoess, MD; <sup>7</sup>Heinz Schaad,  
23 MD; <sup>8</sup>Ulrich Wagner; <sup>9</sup>Sabina de Geest; <sup>1</sup>Philipp Schuetz, MD, MPH, <sup>1</sup>Beat Mueller,  
24 MD

25  
26 <sup>1</sup> Medical University Department, Division of General Internal and Emergency  
27 Medicine, Kantonsspital Aarau, Aarau, Switzerland;

28 <sup>2</sup> Division of Internal Medicine, University Hospital Basel, Basel, Switzerland;

29 <sup>3</sup> Internal Medicine Department, Kantonsspital Baden, Baden, Switzerland;

30 <sup>4</sup> Internal Medicine Department, Kreisspital Muri, Muri, Switzerland;

31 <sup>5</sup> Internal Medicine Department, Spital Zofingen, Zofingen, Switzerland;

32 <sup>6</sup> Internal Medicine Department, Kantonsspital Muensterlingen, Muensterlingen,  
33 Switzerland;

34 <sup>7</sup> Internal Medicine Department, Spital Interlaken, FMI, Interlaken, Switzerland;

35 <sup>8</sup> Swiss Federal Office for Statistics, Neuchâtel, Switzerland

36 <sup>9</sup> Department of Public Health of the Faculty of Medicine, University Hospital Basel,  
37 Switzerland

38  
39 [kutz.alexander@gmail.com](mailto:kutz.alexander@gmail.com); [Daniel.koch@ksa.ch](mailto:Daniel.koch@ksa.ch); [Antoinette.conca@ksa.ch](mailto:Antoinette.conca@ksa.ch);

40 [ciril.baechli@ksa.ch](mailto:ciril.baechli@ksa.ch); [sebastian.haubitz@ksa.ch](mailto:sebastian.haubitz@ksa.ch); [Katharina.regez@ksa.ch](mailto:Katharina.regez@ksa.ch);

41 [Ursula.schild@ksa.ch](mailto:Ursula.schild@ksa.ch); [Zeljka.caldara@ksa.ch](mailto:Zeljka.caldara@ksa.ch); [Fahim.ebrahimi@usb.ch](mailto:Fahim.ebrahimi@usb.ch);

42 [Stefano.bassetti@usb.ch](mailto:Stefano.bassetti@usb.ch); [jens.eckstein@usb.ch](mailto:jens.eckstein@usb.ch); [Juerg-Hans.Beer@ksb.ch](mailto:Juerg-Hans.Beer@ksb.ch);

43 [Michael.Egloff@ksb.ch](mailto:Michael.Egloff@ksb.ch); [vladimir.kaplan@spital-muri.ch](mailto:vladimir.kaplan@spital-muri.ch);

44 [Tobias.Ehmann@spitalzofingen.ch](mailto:Tobias.Ehmann@spitalzofingen.ch); [claus.hoess@stgag.ch](mailto:claus.hoess@stgag.ch);

45 [heinz.schaad@spitalfmi.ch](mailto:heinz.schaad@spitalfmi.ch); [ulrich.wagner@bfs.admin.ch](mailto:ulrich.wagner@bfs.admin.ch);

46 [sabina.degeest@unibas.ch](mailto:sabina.degeest@unibas.ch); [schuetzph@gmail.com](mailto:schuetzph@gmail.com); [happy.mueller@unibas.ch](mailto:happy.mueller@unibas.ch)  
47

## 48 **Summary**

49 Health care costs in Switzerland are high and rising also due to the aging, polymorbid  
50 population. In-hospital treatment is key contributor to the current cost explosions. In view of the  
51 expected demographic evolution, resource allocation becomes a national priority. There is a  
52 lack of evidence-based tools namely for elderly, polymorbid patients to improve the integrative  
53 inter-professional in-hospital care and the transition process in real-life of an emergency and  
54 acute care hospital setting. Also, there is no reference standard for quality benchmarking in  
55 Switzerland which is mandatory to compare quality of different institutions. To address these  
56 issues, we propose a pragmatic multicenter “before-and-after” trial to study the effect of an  
57 inter-professional inpatient management tool (“In-HospiTOOL”) on length of stay and other  
58 patient outcomes. This tool combining several patient discharge measures was developed at  
59 our institution in an intensive multi-professional collaboration for the past ten years. For external  
60 multicenter validation of this tool, we will prospectively include consecutive polymorbid medical  
61 patients upon admission to the medical ward. Because patient-level randomization is not  
62 feasible for an intervention that focuses on the process of care, we will use a quasi-experimental  
63 approach and compare outcomes before and after hospital-wide implementation of the  
64 management tool. We will use time-trend analysis to compare length of stay before and after  
65 tool implementation. Data from other Swiss hospitals from the Swiss Federal Office of Health  
66 (Bundesamt für Gesundheit, BAG) serve as a control population. We target the inclusion of  
67 45`000 patients over an 18-month period in at least five Swiss hospitals. The trial will inform us  
68 whether the “In-HospiTOOL” improves inter-professional team work and thereby reduces length  
69 of stay without negatively impacting subjective and objective markers of patient outcomes. The  
70 large amount of patient data collected within this trial will enable comparison of transition  
71 processes within different hospitals and establish a benchmarking for patient care quality  
72 addressing all three *modules* outlined by the “National Research Program” (NRP) 74 call. Our  
73 trial synergizes funds, national networks and, thus, will likely become a milestone in the current  
74 public healthcare discussions.  
75

## 76 1. Research

### 77 1.1 State of research in the field

78 A comprehensive in-hospital patient management with adequate and human resource  
79 allocation is arguably *the* major challenge of health-care systems, governments, and societies  
80 worldwide [1], especially in elderly, frail, polymorbid and less well educated, or cognitive  
81 impaired patients [2]. Improved diagnostic and therapeutic measures have increased life  
82 expectancy, yet, lead to a growing number of polymorbid, elderly patients. Chronic disease  
83 burden, co-morbidities, and frailty are key risk factors for emergency hospitalization. The trigger  
84 for hospitalization is often a *per se* minor acute disease (e.g. infection of the respiratory tract),  
85 which – on top - disrupts the fragile bio-psycho-social homeostasis of polymorbidity. Too often,  
86 post-acute discharge to a nursing care facility is allegedly inevitable. High demands for medical,  
87 nursing and social care put a strain on our health care resources [3, 4]. *The need for patient*  
88 *management tools to improve the transition process and allocation of health care resources in*  
89 *routine clinical care particularly for the inpatient setting is obvious.*

90 The Swiss health care system has some advantageous approaches in coordination between  
91 patients and physicians as compared to other countries [5]. There is, however, room for  
92 improvement, particularly in terms of accountability for quality, appropriateness, and costs of  
93 health care services [6]. Cantonal responsibility for planning and delivery of health care  
94 services, partial financing of hospitals, as well as provision of subsidies for insurance premiums  
95 makes a national assessment and steering challenging. Federal, cantonal, and private  
96 organizations require and publish benchmark data from hospitals. Recently, internet portals  
97 started to publish comparisons for performance of health care providers – although the reliability  
98 and representativeness of these comparisons can be questioned.

99 Many of these quality-mirroring tools are indeed misleading, as they do not reflect true resource  
100 need and use, especially in elderly, polymorbid patients. Also, there is no validated tool for  
101 optimization of patient flow and discharge process. Some hospitals have developed internal  
102 instruments with more or less sophistication and practicability. Safety, effectiveness, cost-  
103 efficiency, transferability and external validity of these tools are, however, understudied [7, 8].  
104 Health care authorities and hospital executives lack scientific evidence to promote, enforce and  
105 sanction changes or to guide the flow of polymorbid patients. There is, thus, urge to validate  
106 benchmarks and inter-professional tools to improve patient management, flow and length of  
107 stay without compromising patient outcome and functional independence despite chronic  
108 polymorbidity in a pragmatic multicenter setting [9]. *Our comprehensive proposal targets all*  
109 *three modules of the “National Research Program” (NRP) 74.* This is outlined in more detail  
110 below.

111  
112 *Several approaches have addressed in-hospital resource allocation. Yet, a comprehensive*  
113 *patient management tool focusing on the overall in-hospital health care process in polymorbid*  
114 *patients and validated in a multicenter setting – as described in Module 1 of in this proposal -*  
115 *is still missing.*

116 Mis-utilization and suboptimal resource allocation challenges safe and efficient, patient-  
117 centered in-hospital flow from the emergency department (ED), medical ward, and transition to  
118 home or post-acute care facilities [10]. Inadequate use of health care resources is by far more  
119 than technical procedural flaws [11]. Expected benefits of hospitalization must be weighed  
120 against clinical uncertainty, risks associated with inpatient environment [12], and costs  
121 associated with a hospital stay in the health care provider’s site of care decision [13]. Errors  
122 that lead to preventable deaths are more common in polymorbid patients than in other health  
123 care settings [14]. Because the majority of medical patients with chronic illness is hospitalized  
124 through the ED (non-electively), optimized resource use has to start at the ED with an improved  
125 triage. A nontrivial proportion of ED patients are - in retrospect - deemed non-urgent but,  
126 nevertheless, had procedures performed and were admitted to the hospital, including even  
127 intensive care units (ICU) as expression of over-treatment and resource misuse [15].  
128 Timeliness of care is a key target and quality measure to prevent unfavorable outcome [16].  
129 Excessive short-term unscheduled ED readmissions is another key measure of poor quality  
130 [17, 18]. Crowding is also associated with negative patient-relevant outcome, including poorer  
131 care, adverse events, medication errors and lower satisfaction [19, 20]. Lastly, post-acute care  
132 planning - integrated into an accurate risk stratification on admission [21] - has the potential to

133 reduce length of stay and prevent functional disability associated with prolonged hospitalization  
134 [22-24].

135 In the transition from hospital to home, many patients experience adverse drug events [25],  
136 have inadequate follow-up [26], and manifest difficulties with the execution of discharge  
137 instructions [27]. Transitional care has shown beneficial effects on readmission rates [28].  
138 However, the effects of transitional care on mortality are inconsistent [29, 30], and there seems  
139 to be no long-term effect on activities of daily living [31]. Conversely, a reengineered discharge  
140 program decreased hospital utilization by implementing a nurse discharge advocate and a  
141 clinical pharmacist working together to coordinate hospital discharge, educate patients, and  
142 reconcile medications [32].

143 *Conflicting data drove us to design an integrative patient management tool, especially focusing*  
144 *on older chronically ill in-hospital patients while being acutely sick (Module 2).*

145 The optimal organization of routine medical ward care in mostly polymorbid, elderly patients of  
146 general internal medicine received less attention than the management of specific diseases.  
147 Specifically, there is a lack of large studies focusing on polymorbid patients and no  
148 improvement of objective patient outcomes [33]. The inter-professional team care approach  
149 with a comprehensive geriatric in-hospital assessment has been found effective to increase  
150 patients' likelihood of being alive and in their own homes after an emergency admission to  
151 hospital [34]. Conversely, many prior studies have been unable to link interdisciplinary team  
152 care interventions to change in existing metrics, partly because of limitations in methodology  
153 and outcome measures [35].

154  
155 *Recently, innovative concepts to synergize the concepts of implementation science, precision*  
156 *medicine, and learning health care systems have been advocated [36]. Using this experience,*  
157 *we integrate evidence-based strategies (e.g., system change interventions, training,*  
158 *supervision, quality monitoring tools) into real-world practice [37] (Module 3).*

159 Health care providers and payers spend substantial resources in collecting, analyzing, and  
160 reporting data on health care service performance [38]. Beyond the issue of high diversity and  
161 lack of validation of these measures, there is an ongoing dispute which performance data  
162 optimally reflect high quality of care. Some metrics capture health outcomes or processes that  
163 have major effects on overall health, but others focus on activities that may have minimal effects  
164 [38]. *The lack of consensus regarding performance benchmarking data in Switzerland is a*  
165 *major obstacle for quality improvements [39-42].*

166 For an optimal translation into clinical practice, availability and accessibility of high-quality data  
167 is a prerequisite, including accessibility for patients [17]. Several initiatives have proposed to  
168 share data with the public [43]. Availability of anonymized patient-level data from clinical trials  
169 can permit verification of original results, enhancing public trust and accountability, facilitate  
170 other critical research (e.g., evaluation of adverse event rates according to compound class or  
171 subpopulation or identification of surrogate end points), and avert duplicate trials [44]. "Data  
172 dumpsters" must be prevented, i.e., simply making more data openly available without linking  
173 them to relevant documentation and analyses that are applied to improve health [45].

## 174 **1.2 Personal contribution to research in the field**

175 For more than 15 years and supported by the Swiss National Science Foundation (SNF), our  
176 inter-professional, multicenter research group published studies investigating strategies for  
177 improving management of chronic, polymorbid medical patients. Below we summarize our track  
178 record specific to the different *modules* outlined in the NRP 74 call.

### 179 **Module 1: Resource (mis-)utilization & allocation**

180 We have optimized resource use in the fields of emergency triage, antibiotic stewardship and  
181 malnutrition. Also, a main priority of our research was to optimize site of care decisions in the  
182 ED and reduce length of stay in the inpatient setting. In a secondary analysis of a Swiss-wide  
183 multicenter trial on antibiotic stewardship in respiratory tract infections (SNF 3200B0-116177,  
184 ProHOSP) [46], we found that even before 2012 Swiss hospitals with DRG based financing had  
185 a 20% shorter length of stay as compared to fee-for-service (FFS) hospitals without apparent  
186 harmful effects on patient outcomes, satisfaction and quality of life [47]. When looking at  
187 barriers for early discharge, independent of type and severity of disease, misperceived high  
188 severity and expected mortality were predominant reasons why treating physicians, nurses,  
189 patients and their relatives believed that inpatient management was necessary [48, 49]. We  
190 also reviewed psychological distress in medical patients seeking emergency care for somatic

191 reasons [50]. Again supported by the SNF (32003B\_135222, OPTIMA II study) and the Canton  
192 of Aargau (Departement für Gesundheit und Soziales, DGS AG), we validated an inter-  
193 professional risk assessment tool including clinical and biochemical parameters for an  
194 improved risk estimation in polymorbid patients with respiratory infections to safely increase the  
195 outpatient treatment rate and to reduce length of stay [51, 52]. This research was undertaken  
196 in an inter-professional team of nurses, physicians and social care workers often in a  
197 multicenter setting, and including and addressing needs of patients and their relatives.

## 198 **Module 2: Inter-professional collaboration, integral hospital and post-acute patient flow**

199 After revealing inter-professional barriers for earlier patient discharge in patients with  
200 respiratory infections [48, 49, 53], we focused on more heterogeneous, polymorbid medical  
201 inpatients [54-59]. We validated the post-acute care discharge (PACD) score [21] as a highly  
202 predictive nursing risk assessment tool to predict post-acute institutional care thereby allowing  
203 early involvement of social workers to facilitate transition [60, 61]. Similar results were also  
204 found in a very recent large prospective cohort study, investigating >1800 medical and  
205 neurological patients (Conca A., et al., submitted). Later, we completed a randomized  
206 intervention study to investigate the effects of intensified social worker integration (Prins M., et  
207 al., submitted). We implemented successfully a Nurse Led Care (NLC) concept for medically  
208 stabilized patients with high nursing care needs [62-64], to achieve a better functional status, a  
209 higher psychological well-being, and a lower unplanned readmission rate [63, 65, 66], [Conca  
210 A. et al., poster award 3<sup>rd</sup> prize, SAMW, 2015, Berne].

211 Using our inter-professional expertise and up-to-date electronic medical chart technology, we  
212 developed an inter-professional patient management tool ("Visitentool", **Figure 1 and 3**) [Conca  
213 A. et al., poster presentation, CareART, 2014, Basel; Conca A. et al., poster presentation,  
214 Gesundheitssymposium, 2014, St. Gallen]. This platform includes information from (a) the initial  
215 patient assessment to improve decision regarding inpatient vs. outpatient care and for early  
216 prediction of post-acute care needs ("Ersterfassung" including PACD score) and (b) daily  
217 patient-assessments on the ward to improve decisions regarding early patient discharge for  
218 safe transitions from hospital to home or to a post-acute care institution [67]. Using this platform,  
219 physicians, nurses and social workers – of course, adapted to needs and wishes of patients  
220 and relatives, respectively - communicate discharge-relevant information daily using a simple,  
221 intuitive color code, including estimated date of discharge from point of view of each profession.  
222 A comprehensive discharge instruction program including patient education and teach-back  
223 methodology [68] about relevant diagnoses and medication, instruction about follow-up  
224 procedure with coordination of appointments (physicians, nursing home) and clarification of  
225 logistic details (transport, location) is used for all patients [32], [Kutz A. et al., poster award 1<sup>st</sup>  
226 prize, SAMW, 2014, Berne; Kutz A. et al., Swiss Quality Award meeting, 2014, Solothurn].

227 The benefits of our inter-professional efforts became evident in a sub-analysis of the recent  
228 STEP-Study (SNF-Professorship to Prof. Mirjam Christ-Crain). After adjusting for disease  
229 severity in patients with pneumonia, the Kantonsspital Aarau had an adjusted 3-day shorter  
230 mean length of stay as compared to other Swiss cantonal and university hospitals with similar  
231 patient outcomes [69].

## 232 **Module 3: Benchmarking to advice health care authorities and stakeholders**

233 Supported by a grant from the "Swiss Academy of Medical Sciences" (SAMS/SAMW), we  
234 widened our monocentric focus on risk assessment, patient flow and benchmarking in the  
235 multicenter "Triage Study" including more than 7'000 patients in Switzerland, France and the  
236 United States [67, 70]. We found clinical parameters and blood markers from distinct  
237 pathophysiological pathways to be helpful for early risk assessment in a heterogeneous group  
238 of polymorbid medical inpatients independent of underlying diagnosis. We also validated  
239 clinical triage scores such as the Manchester triage system (MTS) [71] for estimating patient  
240 acuity [72]. Very recently, we defined predictors for delayed ED care in international medical  
241 polymorbid patients with acute infections [73], and a larger comparative quality measurement  
242 involving ~3000 patients from different medical disciplines revealed similar results, supporting  
243 the concept that further benchmarking improves health care service (Burgemeister et al.,  
244 submitted). We have established an electronic monitoring and reporting system, enabling  
245 clinical user oriented benchmarking ("Nutzerorientierte Kennzahlen, NOK", **Figure 2**) to monitor  
246 hospital processes, delays in hospital transition and barriers for discharge stratified by  
247 profession (i.e., physicians, nurses, social workers) [51, 70, 71]. For this purpose, we monitor  
248 patient outcome and satisfaction by telephone interviews 30 days after admission with ~15'000


249 patient interviews per year being done at our hospital with an exceptionally high follow-up rate  
 250 of >90%. To date, we gathered data of >30'000 inpatients in a large observational database  
 251 (OPTIMA-TRIAGE). Based on this dataset, several analyses have been published regarding  
 252 outcomes of medical inpatients [50, 70, 73-76] [Kutz A. et al., poster award 2<sup>nd</sup> prize, 7<sup>th</sup>  
 253 Symposium of the Swiss Clinical Trial Organisation, 2016, Lausanne]. We regularly report key  
 254 measures of health care and patient outcomes to the hospital governing board and cantonal  
 255 authorities. We are actively involved in the MIVAG-network ("Masterplan Integrierte Versorgung  
 256 Aargau"), a pioneering cantonal initiative for integral collaboration of pre-, peri-, post-acute and  
 257 chronic health care.

### 258 1.3 Detailed research plan

#### 259 Research question and specific aims

260 We propose a large Swiss-wide trial to investigate the effects of a patient in-hospital  
 261 management tool ("In-HospiTOOL") successfully validated in a single center setting of a  
 262 Medical University Clinic. For this multi-center validation, we will use a "before-and-after" design  
 263 and an interrupted time series (ITS) statistical approach. Nested in this main trial, we will gather  
 264 detailed treatment and outcome data of mainly elderly, polymorbid medical patients during the  
 265 in-hospital stay and 30 days after admission to investigate differences in resource use (*Module*  
 266 *1*), inter-professional collaborations (*Module 2*), and to establish representative benchmarking  
 267 data to promote measurement and display quality of care data [77] across different Swiss  
 268 hospitals (*Module 3*). Thus, as outlined in detail below, we are addressing and synergizing all  
 269 three *modules* of the NRP 74 call with this proposed study. This maximizes efficiency of our  
 270 comprehensive effectiveness research project "In-HospiTOOL" and reduces costs.

271 **Module 1:** In a pragmatic Swiss multicenter study enrolling ~45'000 elderly polymorbid medical  
 272 patients we will study the effects of the multi-professional "In-HospiTOOL" (**Figure 1**) on length  
 273 of stay, our primary endpoint. As secondary endpoints we will explore reasons for delays during  
 274 emergency treatment, in-hospital patient flow, transition to post-acute care, and readmissions  
 275 (synergies of *Module 1* and *2*). The elements of the "In-HospiTOOL" were developed at the  
 276 Medical University Clinic of the Kantonsspital Aarau in an inter-professional effort to optimize  
 277 inter-professionalism and early safe discharge of patients. This tool is now ready to be  
 278 externally validated.  
 279




\*11-item checklist including patient information regarding medical diagnoses, expected risk and prognosis, medication, coordination of follow-up appointments (physicians, nursing home), clarification of logistic details (transport, location).

280 **Figure 1. The "In-HospiTOOL".** An integrative patient management tool. The "In-HospiTOOL" has three components  
 281 involving admission (inter-professional initial assessment, "*Ersterfassung*"), medical ward (inter-professional daily re-  
 282 assessment, "*Visitentool*"), and discharge (inter-professional patient education, reengineered discharge [32]). PACD,  
 283 Post-Acute Care Discharge [21].  
 284

285

286 **Module 2:** Using the data gathered in the main trial (*Module 1*), we will identify differences in  
 287 inter-professional collaboration and barriers across participating hospitals. We will analyze  
 288 factors for delay (i.e., pending diagnostics, medical treatments, administrative and  
 289 organizational elements), effective time to hospital discharge after involving external institutions  
 290 (time from transfer application to transfer), and satisfaction of patients. This allows cross-  
 291 sectional and longitudinal observation of polymorbid patient transition and may help to realize  
 292 an improved health care continuum from initial presentation to the final disposition. This will  
 293 improve our understanding of factors that influence the transition of care from acute to post-  
 294 acute care institutions.

295 **Module 3:** By focusing on outcome data and using a “Delphi approach” within an inter-  
 296 professional sounding board, we will establish a patient risk-adjusted health care monitoring  
 297 system to benchmark patient outcome and satisfaction data. This “Cockpit” approach (**Figure  
 298 2**) supports better comparability of internal quality measures among hospitals in Switzerland.  
 299 At the same time, it provides objective and transparent quality data for future display to patients  
 300 and policy makers. The sounding board will include representatives of all health care  
 301 professions in ambulatory, hospital and post-acute care, insurances, public health, health  
 302 economics and statistics, ethical boards, as well as hospital administrators, cantonal and  
 303 federal authorities (a detailed sounding board constitution is described below in section 2.3 -  
 304 *Implementation partners*). We also plan to disseminate these findings to the public (see section  
 305 2 - *Implementation*).  
 306



307 **Figure 2. The "Cockpit".** For clinical user oriented benchmarking (Nutzerorientierte Kennzahlen) based on patient  
 308 data from our own database including >30'000 medical patients. Quality data from different dimensions is displayed  
 309 comparing different time periods. We report data about in-hospital and 30-day outcomes (i.e. in-hospital and 30-day  
 310 mortality, unplanned readmissions or general practitioner / ED visits), initial ED assessment (i.e. PACD score, ED  
 311 procedure delaying factors), resource use and delaying factors (i.e. ED and medical ward delaying factors, length of  
 312 stay), and patient satisfaction (i.e. satisfaction with ED, ward, and discharge process).  
 313

314

### 315 Theoretical aspects, hypotheses

316 There is a lack of evidence-based tools for management of polymorbid medical patients  
 317 throughout the in-hospital stay with transition to post-acute care institutions. We propose a trial  
 318 that will close this gap by studying the effects of the "In-HospitoOL" on resource use including  
 319 length of stay, inter-professional collaboration, and at the same time will give transparent  
 320 information on outcome data and barriers to transition across several Swiss hospitals.

321 **Module 1:** We hypothesize that implementing the “In-HospITool” in a nationwide multicenter  
 322 setting will significantly shorten length of stay without compromising patient outcomes and  
 323 functional independence. Tight inter-professional collaboration enabled through an electronic  
 324 communication platform (“Visitentool”, **Figure 3**) and identification of the delaying factors in the  
 325 patient flow will result in decreased waiting times contributing to the shortening of length of stay.

326 **Module 2:** Transparent inter-professional communication will reveal factors for delay in these  
 327 polymorbid patients (pending diagnostics, medical treatments, administrative and  
 328 organizational elements) throughout the hospital stay. Doing so, we will identify regional and  
 329 socioeconomic (e.g., health care insurance status) differences in the patient continuum. We  
 330 hypothesize that longitudinal observation of patient flow will further allow us to measure  
 331 effective time from initial request to a post-acute care institution to effective transfer with  
 332 corresponding internal and external delaying factors. We will systematically examine patient  
 333 satisfaction and – based on our own research - hypothesize no reduction of it. Also, we will  
 334 investigate reasons for low satisfaction.

335 **Module 3:** The buildup of a large dataset including comprehensive patient information  
 336 (demographics, clinical, organizational, health insurance status) will be a basis for future data  
 337 sharing in Switzerland [78]. We hypothesize that this dataset from several Swiss hospitals will  
 338 allow identifying associations of management factors and outcome data, thereby helping us to  
 339 better understand how interventions affect patient outcomes. Convocation of a multi-  
 340 professional sounding board with tailored implementation interventions [79] will be inevitable  
 341 for built-up a data warehouse and thus, broad dissemination of our results which has potential  
 342 to improve health care service.  
 343

	ARZT	PFLEGE	SOZIALDIENST
<b>Triage Score:</b>	KSAANGAB / 12.12.2013 03:00:00 Medizinisch stabil	KSAANGAB / 12.12.2013 10:00:00 Austrittsbereit ● PACD d1: 10 ● PACD d3: 10 SPI: -	KSAANGAB / 10.12.2013 16:00:00 Definitiver Termin aber verzögert
<b>Mögl. Austritt:</b>	10.12.2013 Zust. AA + Tel:	12.12.2013	12.12.2013 Zust. SD MA + Tel:
<b>Medizinische Eintrittsdiagnose:</b>	acs	<b>Zielaustrittszustand:</b> mobil mit Hilfsmitteln genügend Kraft/Energie bestehendes Betreuungsnetz angepasst	<b>Austrittsart:</b> Akut- und Übergangspflege
<b>NLC:</b>	Ja	<b>Sozialdienst erforderlich?</b> AH/PH Temporär: AÜP <b>Pflege organisiert:</b>	<b>Austrittsort:</b> Schinznach <b>Anmeldung Sozialdienst</b> ● Anmeldung Sozialdienst Formulare Nachsorgelösung Platz erst dann frei
<b>Verzögerung:</b>			
<b>Austrittsvorstellung:</b>		<b>Patientensicht</b> Patient möchte wieder nach Hause austreten Angehörigensicht Angehörige möchten Patient nach AÜP wieder nach Hause nehmen und bis dahin alles regeln	
<b>Mitteilungen:</b>			
<b>Historie Triagekategorie</b>	<b>Arzt</b>	<b>Pflege</b>	<b>Sozialdienst</b>
<b>Datum</b>	<b>Triage Score</b> <b>mögl. Austritt</b> <b>NLC</b>	<b>Triage Score</b> <b>mögl. Austritt</b> <b>SPI</b>	<b>Triage Score</b> <b>mögl. Austritt</b>
12.12.2013	Medizinisch stabil      10.12.2013    Ja	Austrittsbereit      12.12.2013	
11.12.2013	Medizinisch stabil      10.12.2013    Ja	Austrittsbereit, aber verzögert      12.12.2013	
10.12.2013	Medizinisch stabil      10.12.2013    Nein	Massnahmen eingeleitet      12.12.2013	Definitiver Termin aber verzögert      12.12.2013
09.12.2013	med. stabil, Entlassung verzögert      10.12.2013    Nein	Massnahmen eingeleitet      12.12.2013	
08.12.2013	stabilisierend, Konzept erstellt      14.12.2013    Nein	Massnahmen eingeleitet      12.12.2013	
07.12.2013	stabilisierend, Konzept erstellt      14.12.2013    Nein	Massnahmen eingeleitet      12.12.2013	Extern angemeldet      13.12.2013
06.12.2013	Medizinisch instabil oder unklar      14.12.2013    Nein	PACD => 8 u./od. Nachsorgebedarf      12.12.2013	In Bearbeitung      13.12.2013
05.12.2013	Medizinisch instabil oder unklar      14.12.2013    Nein	PACD => 8 u./od. Nachsorgebedarf      12.12.2013	In Bearbeitung      13.12.2013

344

345

346

347

348

349

350

351 **Achievement of specific aims**352 **Intervention**



353 In five secondary and tertiary care hospitals we will prospectively include consecutive medical  
354 patients upon admission to the medical ward. The main intervention will be the hospital-wide  
355 implementation of the “In-HospiTOOL” with its different components for discharge  
356 management.

357 In a planning and pilot phase (see section 1.4 – *Timetable and milestones*), study site  
358 investigators and staff (physicians, nurses, social service, clinical nurse scientists, information  
359 technology representative) will meet to define a basic orientation program to educate involved  
360 study personnel and hospital collaborators about the intervention. We will teach staff how to  
361 adhere to electronic ED, medical ward, and discharge assessment and to empower patients  
362 and families to attend post-discharge follow-up appointments, manage medications, and  
363 identify and manage symptoms using teach-back methodology [68]. We plan “learning  
364 sessions” in a 6-month interval to troubleshoot and manage issues with the intervention  
365 program.

366 In detail, upon ED admission, we will perform two distinct triage assessments regarding medical  
367 and nursing risk. Physicians will decide about initial site of care (need for in-hospital treatment  
368 *versus* outpatient treatment) and estimate the possible discharge date as a basis for further  
369 inter-professional daily medical ward re-assessments. ED nurses will determine the PACD  
370 score for estimating the need for post-acute care transition to a post-acute care institution,  
371 enabling early involvement of social workers in high-risk patients. Physicians will systematically  
372 collect delaying factors of the ED process.

373 For medical ward patients, we will daily re-assess inter-professionally patient discharge  
374 management using the “Visitentool” (**Figure 3**). Physicians, nurses and social workers  
375 enter/modify the expected discharge date as well as information regarding clinical and  
376 functional stability, and organizational status (using a color code). Entering of factors  
377 responsible for delays in patient flow will be part of the assessment.

378 As a previously published *reengineered discharge* tool has provided significant improvement in  
379 hospital utilization after discharge [32], we have incorporate this tool in the “In-HospiTOOL”  
380 discharge process. Herein, physicians, nurses, and social service will work with patients during  
381 their hospital stay to arrange follow-up appointments, confirm medication reconciliation, and  
382 conduct patient education.

383 We will perform telephone interviews with all patients 30 days after hospital admission to assess  
384 their satisfaction and outcome data. Other than that, patients will receive routine hospital care  
385 without interference by the study team.

### 386 **Intermediate data**

387 **Module 1:** In a first 6-month observational phase, we will generate baseline data of ~15'000  
388 medical patients from five representative Swiss hospitals. The data will include length of stay  
389 (primary endpoint) and data about patient and disease characteristics, demographics, routine  
390 process variables, and outcome data obtained after 30 days with structured telephone  
391 interviews. The data set will include information about the in-hospital process including relevant  
392 diagnostic and therapeutic interventions as well as short-term post-acute care period. During  
393 the 6-month of implementation, again ~15'000 patient data regarding length of stay and a  
394 reduced number of pertinent baseline data will be gathered. After implementation of the “In-  
395 HospiTOOL” we will generate another ~15'000 interventional patient data similar to the initial  
396 observation phase. This approach has the advantage to distinguish effects of the “In-  
397 HospiTOOL” from a difference in secular trends in the controls and intervention group. With this  
398 “before-and-after” design we will gain insights about the effect of “In-HospiTOOL” on resource  
399 use in term of length of stay (primary endpoint), delays during emergency treatment, in-hospital  
400 patient flow, transition to post-acute care, and readmissions (secondary endpoints). This will  
401 be the basis for further monitoring of resource use.

402 **Module 2:** For *Module 2*, in-hospital and outcome data gathered in *Module 1* will be used, but  
403 analyzed differently. A 6-month observational phase will provide cross-sectional data, allowing  
404 inter-hospital analyses of patient management. Specifically, in the intervention phase, we will  
405 focus on the effect of multi-professional collaboration on patient management and flow. We will  
406 gain data about delaying factors (pending diagnostics, medical treatments, administrative and  
407 organizational elements), effective time to hospital discharge after involving external institutions  
408 (time from transfer application to transfer), and satisfaction of patients. Using data from  
409 structured telephone interviews, we will also include information about the functional status of  
410 these polymorbid patients.

411 **Module 3:** We will focus on outcome data gathered during the in-hospital stay and the 30-day  
412 interview in the main trial. Using the “Cockpit” approach (**Figure 2**), we will propose  
413 standardized benchmarking data for future evaluation of quality of care. Main measured  
414 elements will be: in-hospital and 30-day mortality, unplanned readmissions or general  
415 practitioner / ED visits (in-hospital and 30-day outcomes), PACD score, ED procedure delaying  
416 factors (initial ED assessment), medical ward delaying factors, length of stay (resource use,  
417 delays), and satisfaction with ED, ward, and discharge process (patient satisfaction). Collection  
418 of this comprehensive outcome data will define novel and validate currently used quality  
419 measurements which was previously been noted as a major challenge [41].

## 420 **Methods**

### 421 ***Setting and study design***

422 This is a prospective Swiss-wide “before-and-after” trial investigating the effects of a new  
423 patient in-hospital management tool (“In-HospiTOOL”) on length of stay and other outcomes  
424 using two complementary, quasi-experimental analyses: difference in differences and an  
425 interrupted time series (ITS) (*Module 1*). Nested in this multicenter comparative effectiveness  
426 health care research trial, we will gather detailed treatment and outcome data of polymorbid  
427 medical patients during the in-hospital stay and after 30 days to investigate differences in  
428 resource use, inter-professional collaborations (*Module 2*) and to establish representative  
429 benchmarking data to promote measurement and display of quality of care data across Swiss  
430 hospitals (*Module 3*).

431 As of July 2016, the following hospitals have agreed to participate medical department-wide in  
432 the “In-HospiTOOL” study: University Hospital Basel, Kantonsspital Aarau, Kantonsspital St.  
433 Gallen, Luzerner Kantonsspital, Kantonsspital Fribourg. This allows us to collect representative  
434 national-wide patient-centered data from polymorbid patients. All senior executive leaders have  
435 reassured full support for an optimal implementation of the “In-HospiTOOL” in their hospitals.

### 436 ***Data collection process***

437 The study period is divided into a 6-month observational period, a 6-month implementation  
438 period followed by a season-matched 6-month intervention period. The period of “In-  
439 HospiTOOL” implementation in the participating hospitals will be devoted to technical  
440 implementation, training of involved study personnel and physicians, and pilot testing. We will  
441 collect data throughout all three study periods by using electronic medical records and will  
442 contact all patients 30 days after hospital admission by phone interview.

### 443 ***Endpoints***

444 The primary endpoint of this study is length of stay within 30 days after admission including  
445 readmissions during this period (corresponding to *Module 1*). Length of stay will be verified  
446 based on hospital data for the index hospital stay and complemented by 30-day interviews  
447 regarding possible secondary hospitalizations. As described in the statistical plan, we will use  
448 shared data from the Federal Office of Public Health (FOPH, BAG) about length of stay and a  
449 reduced set of basic patient information (i.e., main disease based on DRG code, main  
450 comorbidities, age, gender, health care insurance, home of residence). To grant access of BAG  
451 data we contacted the “Bundesamt für Statistik, BFS” at the end of June 2016. Preparation to  
452 close a data protection contract is ongoing.

453 Secondary endpoints (corresponding to *Module 1 - 3*) include measures of patient-centered  
454 outcomes (i.e., in-hospital and 30-day all-cause mortality, unplanned readmissions or  
455 unplanned general practitioner / ED visits, delaying factors of ED- and medical ward’s flow,  
456 institutionalization, effective time to hospital discharge after involving external institutions (time  
457 from transfer application to transfer), satisfaction with ED, ward, and discharge process,  
458 functional status (incl. quality of life), and overall hospital costs).

459 To study hospital internal processes and effect of inter-professionalism, we will look at  
460 compliance and agreement of the three health professions (physicians, nursing, and social  
461 workers) in the use of “In-HospiTOOL”, and delays from the anticipated to the effective  
462 discharge date as compared to discharge date anticipated by the different health care  
463 professionals on admission and during the course of the hospital stay. We will use the above  
464 mentioned outcome data set as benchmark to establish a risk-adjusted resource and quality  
465 cockpit to compare different hospitals and demographics (corresponding to *Module 3*).

### 466 ***Independent variables***

467 The primary exposure variable of interest is the intervention, i.e. the implementation of the “In-  
 468 HospiT00L”. As outlined in the statistical plan, we will adjust our model to the following  
 469 covariates: demographics (age, gender, health care insurance, home of residence [home  
 470 versus facility]), main diagnosis (grouped using the “14 - International Classification of Diseases  
 471 (ICD-10)” [80]), comorbidities (using the Elixhauser comorbidity index [81]), and study center.

#### 472 **Statistical analysis and sample size**

473 **Module 1:** Because patient-level randomization is not feasible for an intervention that focuses  
 474 on the process of care and differences in the patient population may occur due to  
 475 epidemiological variations, we will assess the effects of introducing the “In-HospiT00L” using  
 476 two complementary, quasi-experimental analyses. This statistical approach was recently used  
 477 successfully by one of our collaborators (Prof. E. J. Orav, Harvard School of Public Health,  
 478 USA, see **Figure 4**) [82].


479 We will adjust outcome analyses in the difference in differences and interrupted time series  
 480 (ITS) model for important covariates such as age, gender, health care insurance, home of  
 481 residence, main diagnosis, comorbidities, and study center. In regard to sample size  
 482 considerations, we will include consecutive patients in each hospital over a 6-month period for  
 483 the observation, implementation, and the intervention period. Given the large number of  
 484 patients per clinic seen in routine (i.e. between 4'000 and 8'000) per year, we estimate to enroll  
 485 approximately ~45'000 patients over 18 month of recruitment (6-month observation,  
 486 implementation, and intervention period, each). This large amount of patient data will provide  
 487 strong power to look into the effect of introducing a patient care tool in the overall medical  
 488 hospitalized patient population and allow for subgroup analyses, as well as important post-hoc  
 489 analyses.

#### 490 Difference in differences

491 To determine whether there will be an overall effect on length of stay after implementing the  
 492 “In-HospiT00L”, we estimate a patient-level logistic regression model. It will include lengths of  
 493 hospital stay of “BAG” hospitals, all risk adjusters listed above, a variable for elapsed weeks to  
 494 account for secular trends, and indicators for intervention period, intervention hospitals, and  
 495 their interaction. The dependent variable will be length of stay (days in hospital) within 30 days.  
 496 By testing for an interaction between intervention period and intervention population, we will  
 497 assess whether there is a difference in the change in length of stay over time between the two  
 498 control and the intervention populations (difference in differences). The difference in differences  
 499 design does not require that the control and intervention groups have similar baseline  
 500 characteristics but rather assumes that both groups would have experienced similar changes  
 501 in outcomes over time without the interventional program.

#### 502 Interrupted time series (ITS)

503 We will analyze the trends in  
 504 length of stay from start of  
 505 observation through the end of  
 506 intervention period (18 months).  
 507 For this purpose, we will  
 508 conduct an interrupted time  
 509 series (ITS) as a sensitivity  
 510 analysis. We will implement the  
 511 interrupted time series (ITS)  
 512 using generalized estimating  
 513 equations (GEE), to examine  
 514 linear trends in weekly, hospital-  
 515 level, risk-adjusted length of  
 516 stay. We will analyze the  
 517 change in trend between all  
 518 three time periods. This  
 519 approach has the advantage to  
 520 distinguish an effect of the  
 521 intervention from a difference in  
 522 underlying secular trends in the  
 523 control and intervention



**Figure 4. Interrupted time series (ITS) model.** Schematic example showing readmission rates before (observation phase), during (implementation phase), and after (intervention phase) introduction of an intervention program.

524 populations (which could produce a misleadingly significant difference-in-differences result)  
525 and can also help to determine whether the intervention effects will sustain. We will calculate  
526 weekly-adjusted length of stay using linear GEE that includes all lengths of stay from the control  
527 and intervention populations and all above mentioned risk variables. This model also includes  
528 indicators for each week and interactions of these with an indicator for the control population.  
529 We will center all risk factors on their overall means and suppress the intercept to avoid omitting  
530 any month indicators. We will graph weekly length of stay for all populations over time and use  
531 the estimated weekly rates for control and intervention populations to calculate a weekly  
532 difference between the two populations. We then determine whether there is any overall  
533 decrease in adjusted weekly length of stay in the intervention period and whether there will be  
534 a time trend effect caused by the interventional program [83]. Because of suspected evidence  
535 of non-stationarity data we will use an autoregressive integrated moving average (ARIMA)  
536 model, with a 6-month autoregressive term to predict future impact of implementing the "In-  
537 HospiT00L".

538 To summarize, we will use four statistically hypothesis tests during each period: First, are there  
539 significant trends in length of stay change during the period? Second, will the trend differ  
540 between the control and intervention populations (the interaction between time and control or  
541 intervention conditions) during the period? Third, will the trend during the intervention period  
542 differ from the trend during the observation period within all three conditions? Fourth, will the  
543 magnitude of the change in trend between the intervention and the observation period differ  
544 between the three conditions (the interaction between the change in slope and intervention or  
545 control conditions)? We will also use this models and tests for above mentioned secondary  
546 outcomes.

547 **Module 2:** To analyze regional and socioeconomic variations in quality of the transition  
548 process, we will cross-sectionally compare the patient management among participating  
549 hospitals. This qualitative part will give a summary of parameters that are relevant for the  
550 diagnostic, therapeutic, and discharge process (e.g., reasons for delayed hospital discharge  
551 from each professions` perspective). Also, we will focus on regional differences in disposability  
552 of post-acute care facilities and investigate associations with time to effective hospital discharge  
553 and length of stay using regression analysis as appropriate. Patient`s satisfaction in terms of  
554 the whole transition process will be another essential focus of investigation. To investigate  
555 trends over time, we will longitudinally analyze the impact of the "In-HospiT00L"  
556 implementation. Depending on our available resources, we will develop a protocol to further  
557 investigate differences in costs among hospitals in a separate cost analysis (a detailed analysis  
558 plan will be developed).

559 **Module 3:** Using a Delphi approach we will invite a group of selected health care authorities  
560 (see section 2.3 - *Implementation partners*) to define further measures similar to **Figure 2**. We  
561 will study confounding factors for these quality outcomes for which analyses need to be  
562 adjusted to allow fair comparisons between hospitals. We will display data adjusted for  
563 confounders in a quantitative manner stratified according to time point and patient population.  
564 This will enable to monitor quality alterations and performance metrics over the study time as  
565 well as in the long-term process. Based on this benchmarking, again together with  
566 stakeholders, in a second study period we will define sustainable strategies for wider  
567 implementation and dissemination of study results and the "In-HospiT00L" *per se*.

568  
569 For all analyses, significance will be based on 95% confidence intervals. Data management  
570 and analyses will be performed with STATA statistical software (StataCorp).

## 571 **Target population**

### 572 ***Intervention population***


573 To reflect "daily practice", we will include consecutive adult medical inpatients independent of  
574 their diagnosis during the observation, implementation, and intervention period into the analysis  
575 - similar to an intention-to-treat approach. Except for non-medical and non-adult patients there  
576 will be no exclusion criteria. As a quality control study with an intervention focusing on the  
577 hospital level rather than the individual patient level, we will ask the ethical review boards for a  
578 waiver of individual patient informed consent. This was granted for a similar monocentric pilot  
579 study in Aarau (EK 2012/059).

### 580 ***Control population***

581 For our statistical approach as outlined above, we request data from the “BAG” to provide a  
 582 nationwide comparability. We will use data on length of stay (primary endpoint) and age,  
 583 gender, health care insurance, home of residence, main diagnosis, comorbidities, and study  
 584 center for adjustment.

### 585 **Expected results**

586 As illustrated in **Figure 5**, we expect an inclusion rate of 15`000 patients in the intervention  
 587 population for all three study periods (observation, implementation, intervention), each (total  
 588 study population n~45`000). Based on our monocentric experience we expect the “In-  
 589 HospiTOOL” to have a strong effect on the inter-professional team work in this polymorbid  
 590 setting which results in reduction in length of stay of at least 1 day [69]. We also expect that  
 591 patient outcomes are not negatively affected by the intervention with no increase in ICU  
 592 admission, mortality, unplanned readmission, unplanned general practitioner visits and low  
 593 satisfaction. A safe reduction of length of stay will have positive implication on overall hospital  
 594 costs.  
 595



596 **Figure 5. Main study timeline.** Endpoint data will be collected throughout 18 months during the observation,  
 597 implementation, and intervention period, and will be weekly reported. Education will be provided during the  
 598 implementation and intervention period. Learning sessions are thought to compile intermediate data and to improve  
 599 implementation and intervention processes. “BAG”, Bundesamt für Gesundheit.  
 600

601

### 602 **1.4 Timetable and milestones (Management Plan)**

603 Our study addresses and synergizes research question in all three *modules*. We have already  
 604 involved all leading authorities of the above mentioned hospitals and will organize an  
 605 investigator meeting upon permission to start the study. For the intervention trial, we will do a  
 606 6-month planning and pilot-phase starting in January 1, 2017. This will be followed by a 6-  
 607 month observational period with patient-centered data generation and 30-day follow-up phone  
 608 interviews. The 6-month implementation period from January 1, 2018, through June 30, 2018  
 609 will be largely devoted to the technical implementation of the “In-HospiTOOL” in all involved  
 610 interventional hospitals, training of involved personnel, tight monitoring by study nurses, and  
 611 30-day follow-up phone interviews. The intervention period will take place from July 1, 2018,  
 612 through December 31, 2018. Thereafter, we have dedicated 18-month to complete the 30-day  
 613 follow-up of all patients, and finish all endpoints of the *modules 1-3* as well as ancillary projects.  
 614

Objectives	Jan- Jun 2017	Jul- Dec 2017	Jan- Jun 2018	Jul- Dec 2018	Jan- Jun 2019	Jul- Dec 2019	Jan- Jun 2020	Jul- Dec 2020
<b>Main Study</b>								
Ethical approval, investigator meeting (2x), planning & pilot phase	■		■					
Scientific review, incl. publication	■							
Observational phase, active patient enrollment		■						
Implementation phase, active patient enrollment			■					
Intervention phase, active patient enrollment				■				
Finishing follow-up, database finalization					■			
Data analysis and manuscript preparation				■	■			
Manuscript publication						■		
<b>Secondary analyses as preparation for national-wide dissemination</b>								
Data analyses					■	■	■	■
Manuscript preparation and publication							■	■
<b>Administration</b>								
Benchmarking, monitoring, process optimizing				■	■	■	■	■
<b>Dissemination, national-wide implementation</b>								
Sounding board meeting, preparation*						■	■	■
<b>Requested funding period (4 years)</b>								

**Table 1.** Schedule and milestones of the In-HospitoOL-Study; \*Details and milestones of the dissemination process are outlined in section 2. (*Implementation*).

615  
616

617

## 618 2. Implementation

619 There is a gap between innovations in health care research and their implementation in routine  
620 practice [84]. Four key factors ensure that “In-HospitoOL” is an important project for health  
621 authorities, hospital administrators, health care professionals, and patients to benefit from  
622 scientific advances with sustained effects for routine clinical care [36]. First, we propose a  
623 pragmatic comparative effectiveness trial involving major Swiss hospitals in which a number of  
624 management tools will be tested in clinical practice (“real-life”) in consecutive patients  
625 addressing patient-relevant, subjective and objective outcome parameters [85]. Second,  
626 implementation of the “In-HospitoOL” will involve all key players in each hospital from nursing  
627 and social worker as well as physician staff and hospital administration. Third, the study  
628 requires permanent adaption of the electronic health record systems. Assuming a positive effect  
629 of this tool concerning resource use, we expect a high motivation of other institutions to adapt  
630 their processes in a similar way. Fourth, we will publish results giving details about the specific  
631 items included in the “In-HospitoOL” not only as research papers but also selected content on  
632 classical news media (interviews with newspaper, radio, TV) and the web, including social  
633 media (e.g. Facebook, twitter) to encourage other institutions, patients and the public to discuss  
634 and adapt with lower barriers. Importantly, classical media (newspaper, radio, TV) are not to  
635 be neglected since (potential) patients and their relatives interested in our study are elderly and,  
636 thus, not familiar with novel web-media. The strong network of involved exponents from  
637 different professions will allow to broadly disseminate of our results from *module 1, 2* and *3* into  
638 the public.

### 639 2.1 Previous achievements in knowledge and technology transfer

640 Our previous research and clinical expertise comprises different elements important to the  
641 successful completion of the In-HospitoOL-study. We have profound methodological know-  
642 how acquired through playing key roles in the conduct of various multicenter randomized  
643 controlled trials involving several Swiss and national institutions [46, 69, 86-89]. Results of  
644 these trials have had a profound impact on international guidelines. First, reduced corticosteroid  
645 use for patients with chronic obstructive pulmonary disease (COPD) exacerbation has been  
646 included in the recent GOLD guidelines [88]. Second, measurement of procalcitonin for

647 antibiotic decision making has been included in the recent surviving sepsis campaign guidelines  
648 [90, 91] and international respiratory medicine guidelines [46, 87, 92]. Third, corticosteroids  
649 have now been suggested for use in pneumonia patients based on a recent trial from our  
650 research network [69].


651 In addition to knowledge transfer from clinical trials, we have established a new insulin algorithm  
652 in our clinic work for inpatient management [93]. This algorithm is now integrated into our  
653 medical record system (KISIM, Cistec). It is also being used in the University Hospital Zürich  
654 and other Swiss hospitals using the same electronic medical record system.

## 655 2.2 Activities planned

### 656 Plans for dissemination

657 The use of data generated in this study, experience and networking of sounding board  
658 members (see section 2.3), and key elements of implementation science will improve health care,  
659 health systems, and finally patients' health. We will refer to tailored implementation interventions,  
660 being strategies that are designed to achieve desired changes in healthcare practice based on  
661 an assessment of determinants of healthcare practice [94]. Four main groups of variables that  
662 interact with adoption of innovations were previously identified (**Figure 6**) [95]: the external  
663 environment (e.g. new payment models), the structure of the organization (e.g. integrated  
664 delivery systems), the characteristics of the innovation (e.g., the strength of the evidence  
665 supporting it), and the processes used (e.g., bottom-up vs top-down decision making). This  
666 framework not only focuses on how to more quickly adopt and spread innovations that will  
667 benefit patients but also helps to understand how organizations eliminate treatments, practices,  
668 and policies that do not benefit patients (optimized resource allocation). Whether hospitals and  
669 health care institutions can do this better than others need to be identified. Health care delivery  
670 innovations such as the elements of the "In-HospiTOOL" focus on groups of patients defined  
671 by factors such as the site of care or the complexity of polymorbid's clinical situation. Although  
672 practicing physicians and the patients for whom they provide care are affected by these  
673 innovations, decision making about their use will be the primary responsibility of all involved  
674 practice managers and organizational leaders (stakeholders). This is crucial because of its  
675 complexity with diverse engaged individuals from different organizational levels and sometimes  
676 beyond. Existing evidence suggests that such innovations will have substantial potential to  
677 improve health care and reduce costs. Therefore, the implementation science framework can  
678 be used to identify the barriers to their successful implementation and strategies for overcoming  
679 them [96]. Furthermore, we must be aware of two important points: recognition that the  
680 increasing burden of chronic illness in the Swiss population cannot be addressed without  
681 engaging patients and their caregivers in effective self-care, behavior change, and chronic  
682 disease management; and the need to better align treatment choices with patients' well  
683 informed preferences and values through shared decision making. These changes in practice  
684 will implicate a fundamental change in the historical framework of the health care provider as  
685 expert and the patient as passive recipient.

686 As collaborators in the framework will be representatives from the hospitals (physicians, nurses,  
687 social workers, information scientists, controllers, etc.), general practitioner responsible for out-  
688 patient and pre-hospital setting (ARGOMED, largest Swiss managed care network of general  
689 practitioners), post-acute care facilities, health care authorities (DGS), health care insurances  
690 (santésuisse, curafutura), inter-professional board of health care management experts  
691 (Institute for Systemic Management and Public Governance, IMP-HSG (University St. Gallen)),  
692 and public benchmarking and internet providers (Nationaler Verein für Qualitätsentwicklung in  
693 Spitälern und Kliniken [ANQ], Spitalfinder, etc.). This will allow us built-up a – on purpose –  
694 heterogeneous sounding board involving all important stakeholders and authorities in a  
695 comprehensive health care process, including policies and financiers. Based on this sounding  
696 board, we will be able to analyze external environment and organization characteristics, as we



**Figure 6.** Framework for analyzing the adoption of health care innovations (adapted from [37]).

706 know that complex interventions may work best if tailored to local circumstances rather than  
707 being completely standardized [97]. Doing so, adoption of the “In-HospiTOOL” will be facilitated  
708 by direct feedback of the stakeholders, enabling continuous immediately improvement of  
709 processes. Hence, long-term collaboration between hospitals and other health care providers  
710 will be strengthened, leading to an improved and step-less treatment continuum of chronic ill  
711 patients.

712 One major aim is to broadly disseminate our comprehensive patient-centered data, gathered  
713 in the observational as well as in the interventional phase. First, we intend to give patients and  
714 stakeholders a better understanding of the multifaceted health care processes in Switzerland.  
715 Knowledge about this elementary integrative health care process will translate into optimized  
716 transparency and education. In this context, we will publish data about resource use, patient  
717 outcome, patient satisfaction, functional status, and overall hospital costs; on the one hand in  
718 a public version at hospitals websites and on the other hand in diverse scientific journals as  
719 well as in patient brochures, issued by health care providers, health care insurances, and  
720 government. This will finally have a competitive influence on national-wide health care providers  
721 as well as on financiers and government that will open discussion about new recompense and  
722 payment strategies in this increasing polymorbid patient population. As already mentioned by  
723 the SNF, the “Wissens- und Technologie Transferstelle (WTT)” of the University Basel will play  
724 a crucial part in definition of dissemination strategies.

## 725 **2.3 Implementation partners: references and contributions**

### 726 **Sounding Board of Participating Hospitals, Stakeholders and Government Authorities**

727 In the past years we have built a multi-faceted network of pre-hospital, in-hospital and post-  
728 acute care partners. For this project, we will be advised by key academic, executive,  
729 administrative, clinical stakeholders and health care representatives.

730 I) General practitioner responsible for out-patient and pre-hospital setting  
731 - ARGOMED, largest Swiss managed care network of general practitioners: CEO K. Züger,  
732 President Dr. W. Czerwenka  
733

734 General practitioners will play an elementary part in improving transition of patients from the  
735 out-hospital to the in-hospital setting and *vice versa*. This will be an indispensable step in  
736 strategies of improving and simplifying data exchange.  
737

738 II) Chief executives, physicians, nurses, social workers of participating hospitals  
739 - University Hospital Basel: CEO Dr. W. Kübler, Prof. S. Bassetti, Prof. S. de Geest, Dr. J.  
740 Martin  
741 - Kantonsspital Aarau: CEO Dr. R. Rhiner, Prof. B. Müller, Mrs. H. Weber  
742 - Kantonsspital St. Gallen: CEO Dr. H. Germann, Prof. M. Brändle, Mrs. N. Mösli, Mrs. B.  
743 Schoop  
744 - Luzerner Kantonsspital: CEO B. Fuchs, Prof. C. Henzen, Mr. M. Döring, Mr. D. Gralher  
745 - Kantonsspital Fribourg (HFR): CEO Mrs. C. Käch, CMO Dr. I. Spicher  
746

747 Leading authorities of their hospitals and disciplines provide full support in performing this study  
748 with a consecutively inclusion of medical in-patients and a large adherence in using the study  
749 templates (elements of the “In-HospiTOOL”).  
750

751 III) Post-acute care facilities  
752 - Klinik Barmelweid: CEO Mr. B. Stierlin, Dr. Thomas Sigris  
753 - Rehaklinik Bad Schinznach: CEO Mr. B. Schläfli, Dr. St. Bützberger  
754 - Spitex of Canton of Aargau: Mr. H. R. Häny, Mrs. P. Baur  
755 - Pflegeheim Lindenfeld: CEO Mr. T. Holliger, Dr. I. Amrhein, Mrs. D. Deubelbeiss  
756

757 Post-acute care facilities will play an elementary part in improving transition of patients from the  
758 acute setting hospital to their institution. Based on the PACD, patients will be registered earlier  
759 in a post-acute care facility, enabling an optimal preparation at an earlier stage. Doing so,  
760 resources will be shared more efficiently. Personal contacts of institutions from the cantons  
761 Basel-Stadt, St. Gallen, Lucerne, and Fribourg pending upon funding of the proposal.  
762

763 IV) Health care authorities  
764



765 - Cantonal: Departement für Gesundheit und Soziales (DGS) AG: Mr. U. Zanoni, Head "MIVAG"  
766 (Masterplan Integrative Versorgung / eHealth Aargau)  
767 - Federal: Bundesamt für Gesundheit (BAG), Bundesamt für Statistik (BFS)

768  
769 We asked the BAG and BFS for access to nationwide patient- and hospital-centered data from  
770 registries. Government authorities will be significantly involved in wider implementation and  
771 dissemination of the studies' results. They will become important in defining new recompense  
772 and payment systems.

#### 773 V) Health insurances

774 - selected health insurances (e.g. Helsana, CEO Mr. D. H. Schmutz, President Prof. T. Szucs  
775 is member of the Medical Faculty of the University of Basel as the PI of this grant)  
776 - santésuisse, curafutura: (personal contacts pending upon funding of the proposal)

777  
778 Health insurance authorities will be significantly involved in wider implementation and  
779 dissemination of the studies' results. They will become important in defining new recompense  
780 and payment systems together with government authorities.

#### 781 782 VI) Public benchmarking and internet providers

783 - Nationaler Verein für Qualitätsentwicklung in Spitälern und Kliniken (ANQ): CEO Dr. P. Busch  
784 - <http://www.spitalfinder.ch/de/>  
785 - <http://www.spitalinformation.ch>

786  
787 Public benchmarking and internet providers will have a supportive role in defining further  
788 patient-centered outcomes. They will give essential support in establishing a multi-health care  
789 institution data warehouse and in continuous benchmarking and optimizing strategies. Personal  
790 contacts pending upon funding of the proposal.

#### 791 792 VII) Inter-professional Board of Health Care Management Experts

793 - Institute for Systemic Management and Public Governance, IMP-HSG (University St. Gallen),  
794 St. Gallen: Prof. J. Rüegg-Stürm (the PI is member of the "executive circle" led by Prof. Rüegg-  
795 Stürm)  
796 - Department of Psychology, University of Berne: Fr. Prof. P. Perrig (ongoing thesis project)  
797 - Department of Nursing Development and International Collaboration, Swiss Nursing  
798 Association: Mrs. R. Koch  
799 - Universities of Applied Sciences, Department of Nursing; Winterthur, Prof. A. Koppitz; Berne,  
800 Prof. S. Hahn; St. Gallen, Prof. B. Senn

#### 801 802 VIII) Statistical collaboration

803 - Harvard school of public health, Boston, USA: Prof. E. J. Orav (personal contact of Prof. Ph.  
804 Schütz, co-author of the grant application)

805  
806 Using the expertise of several health care management experts we will define further secondary  
807 analyses of our study to generate a multi-faceted implementation strategy and a broad  
808 dissemination of our results.

## 809 **2.4 Timetable and milestones**

810 While performing the In-HospiTOOL-study we will broaden our sounding board that will facilitate  
811 wider implementation of our results. After obtaining first results, we will organize a sounding  
812 board meeting in the late 2019 to define further steps of dissemination, since namely in  
813 research - in our experience - learning is also a result of doing. Thereby, if feasible, additional  
814 ancillary analyses will be performed. Increasing the impact on the Swiss health care system. In  
815 this context, health care providers, health insurances and government authorities will publish  
816 patient-centered data about previously defined outcomes, starting in the first half of 2020. In  
817 addition, leading authorities of the hospitals will decide about a continuation of the "In-  
818 HospiTOOL". Benchmarking and continuous process optimizing will be performed analogously.  
819 After a further 1-year implementation and dissemination in previous or new hospitals, health  
820 insurances and government authorities will discuss new recompense and payment systems.  
821 Depending on Swiss long-term results international validation may be an appropriate medium to  
822 finally introduce and fix the "In-HospiTOOL" in the (inter-)national health care system.

823

Objectives	Jan- Jun 2019	Jul- Dec 2019	Jan- Jun 2020	Jul- Dec 2020	Jan- Jun 2021	Jul- Dec 2021	Jan- Jun 2022	Jul- Dec 2022
<b>Preparation of wider dissemination and implementation</b>								
Sounding board meeting, preparation								
Patient-centered data publishing								
<b>Secondary analyses as preparation for national-wide dissemination</b>								
Data analyses								
Manuscript preparation and publication								
<b>Administration</b>								
Benchmarking, monitoring, process optimizing								
<b>Dissemination, national-wide implementation</b>								
Stakeholder meeting, consensus conference, preparation*								
<b>Requested funding period (4 years)</b>								
<b>Additional funding request for further dissemination</b>								

824 **Table 2.** Schedule and milestones of the implementation and dissemination strategy of “In-HospitoOL” findings.

825

### 826 **3. Significance**

#### 827 **3.1 Scientific significance**

828 Clinical trials that are embedded into usual care (“comprehensive effectiveness research”) have  
 829 the potential to yield outcomes of great relevance to the institutions where they are performed  
 830 and at the same time to yield information that may be generalizable to the health care system  
 831 at large [85].

832 Health care costs in Switzerland are high and rising due to the aging, polymorbid population.  
 833 Scientific evidence regarding performance, safety and cost-effectiveness of specific integrative  
 834 multi-professional care models tailored to the Swiss health care system is largely lacking. The  
 835 “In-HospitoOL” is an integrative multi-professional inpatient management tool that enables a  
 836 better understanding of the multifaceted health care processes and will close this gap. Through  
 837 a standardized but at the same time individualized approach, it will improve the inter-  
 838 professional management of patients from ED admission to hospital discharge to home or a  
 839 nursing care facility. This will translate into optimized transparency, resource use, patient  
 840 outcome and satisfaction, functional status, and overall hospital costs. We expect that the  
 841 results of the In-HospitoOL-study will be widely, directly and rapidly applied – and indeed, will  
 842 contribute to a new standard of (inter-)national health care.

843 In addition to the main interventional trial, gathering of data from around ~45`000 patients from  
 844 at least 5 Swiss hospitals will help to establishing a national-wide framework involving important  
 845 stakeholder of the Swiss health care system. Networking is a prerequisite for improving  
 846 sustainable patient-centered health care delivery with an optimal resource allocation. This will  
 847 lead to a more efficient patient flow with decreased risk for hospital associated adverse  
 848 outcomes. Also, the large dataset will allow to compare different outcomes of different patient  
 849 populations across different hospitals with each individual health care strategies. We will also  
 850 be open to share our data with other national health care researchers for secondary analyses.  
 851 In addition, health insurance and policy authorities will largely profit from these data to  
 852 conceptualize new reimbursement strategies in the polymorbid inpatient setting.

853 Such embedded comparative effectiveness research relies on the engagement of care  
 854 providers and health care systems as active partners in defining the objectives of the research  
 855 rather than as passive consumers of its product [85]. This pragmatic research will enforce  
 856 rethinking and redefining traditional ethical and regulatory standards (including informed  
 857 consent and engagement in research) in this paradigm of low risk.

#### 858 **3.2 Social and economic significance**

859 Many patients are cared for by their relatives and families, putting a large strain on them. In  
 860 Switzerland, this unpaid care of adult patients was accounted for 2`414 Mio. Swiss francs in

861 2013 [98]. Comprehensive discharge planning without family support is unlikely to be possible,  
862 thus, early involvement of relatives is inevitable. Herein, the “In-HospiT00L” will play an  
863 important role, by enabling an early inter-professional communication including patient and  
864 relatives, which is fundamental in an optimized discharge planning. In addition, by creating  
865 transparency of the entire health care process, polymorbid patients and their relatives will be  
866 better informed about relevant, patient-centered outcome measures including satisfaction,  
867 enhancing hospitals` contest in improving health care quality [77].

868 Our study will have important implication in generating evidence in this new research field. In  
869 terms of a “smarter medicine” the “In-HospiT00L” rigorously uncovers health care service  
870 misuse in this large and complex polymorbid patient population and will serve as a milestone  
871 in establishment of an improved patient flow. Our project will animate new generation health  
872 care personnel and researchers to actively participate in defining novel strategies to sustainably  
873 increase patients` safety without further cost explosion.

874 Given the continuous aging of the Swiss population [99], the proportion of polymorbid patients  
875 will further rise, and traditional health care models are no longer suitable for this challenge as  
876 they are still designed for mono-morbid patients [100]. In consequence, expenses are reaching  
877 new levels yearly, with a national increase from 10.3% of gross domestic product (GDP) (62.5  
878 billion Swiss francs) to 11.1% of GDP (71.2 billion Swiss francs) within 2010 and 2014 [101].  
879 Daily costs in an average Swiss somatic hospital were 1'690 Swiss francs in 2011. In 2011, the  
880 average hospital stay was 7.5 days with 1.36 million hospitalizations [102]. Herein, the “In-  
881 HospiT00L” will support containment of health care expanses in the in-hospital setting, mainly  
882 due to identification and reduction of avoidable resource misuse. As outlined above,  
883 interventions in the Medical University Clinic of Kantonsspital Aarau have already reduced  
884 length of stay by approximately 3 days as compared to other tertiary care hospitals in  
885 Switzerland [69]. Envisioning that similar improvements will be achieved by implementation of  
886 “In-HospiT00L” in other hospitals, we assume that costs may drop also on a nation-wide level.  
887

#### 888 **4. References mentioned in this proposal (own research in bold)**

- 889 1. Barnett, K., et al., *Epidemiology of multimorbidity and implications for health care, research, and*  
890 *medical education: a cross-sectional study*. Lancet, 2012. **380**(9836): p. 37-43.
- 891 2. Mercer, S.W., et al., *Multimorbidity and the inverse care law in primary care*. BMJ, 2012. **344**: p. e4152.
- 892 3. Bahler, C., et al., *Multimorbidity, health care utilization and costs in an elderly community-dwelling*  
893 *population: a claims data based observational study*. BMC Health Serv Res, 2015. **15**: p. 23.
- 894 4. Kadam, U.T., et al., *Chronic disease multimorbidity transitions across healthcare interfaces and*  
895 *associated costs: a clinical-linkage database study*. BMJ Open, 2013. **3**(7).
- 896 5. Selby, K. and S. Edwards, *Time-Based Billing: What Primary Care in the United States Can Learn From*  
897 *Switzerland*. JAMA Intern Med, 2016.
- 898 6. Biller-Andorno, N. and T. Zeltner, *Individual Responsibility and Community Solidarity--The Swiss*  
899 *Health Care System*. N Engl J Med, 2015. **373**(23): p. 2193-7.
- 900 7. Boyd, C.M., et al., *Clinical practice guidelines and quality of care for older patients with multiple*  
901 *comorbid diseases: implications for pay for performance*. JAMA, 2005. **294**(6): p. 716-24.
- 902 8. Hughes, L.D., M.E. McMurdo, and B. Guthrie, *Guidelines for people not for diseases: the challenges of*  
903 *applying UK clinical guidelines to people with multimorbidity*. Age Ageing, 2013. **42**(1): p. 62-9.
- 904 9. Roland, M. and C. Paddison, *Better management of patients with multimorbidity*. BMJ, 2013. **346**: p.  
905 f2510.
- 906 10. O'Leary, K.J., et al., *Interdisciplinary teamwork in hospitals: a review and practical recommendations*  
907 *for improvement*. J Hosp Med, 2012. **7**(1): p. 48-54.
- 908 11. Huang, C., et al., *Implementation of proven interventions in general medical inpatients: development*  
909 *and evaluation of a new quality indicator for drug therapy*. Qual Saf Health Care, 2008. **17**(4): p. 269-  
910 74.
- 911 12. Classen, D.C., et al., *'Global trigger tool' shows that adverse events in hospitals may be ten times greater*  
912 *than previously measured*. Health Aff (Millwood), 2011. **30**(4): p. 581-9.
- 913 13. Sabbatini, A.K., et al., *In-Hospital Outcomes and Costs Among Patients Hospitalized During a Return*  
914 *Visit to the Emergency Department*. JAMA, 2016. **315**(7): p. 663-71.
- 915 14. Hogan, H., et al., *Preventable deaths due to problems in care in English acute hospitals: a retrospective*  
916 *case record review study*. BMJ Qual Saf, 2012. **21**(9): p. 737-45.
- 917 15. Hsia, R.Y., A.B. Friedman, and M. Niedzwiecki, *Urgent Care Needs Among Nonurgent Visits to the*  
918 *Emergency Department*. JAMA Intern Med, 2016.
- 919 16. Le, S.T. and R.Y. Hsia, *Timeliness of care in US emergency departments: an analysis of newly released*  
920 *metrics from the Centers for Medicare & Medicaid services*. JAMA Intern Med, 2014. **174**(11): p. 1847-  
921 9.

- 922 17. Lindsay, P., et al., *The development of indicators to measure the quality of clinical care in emergency*  
923 *departments following a modified-delphi approach.* Acad Emerg Med, 2002. **9**(11): p. 1131-9.
- 924 18. Schull, M.J., et al., *Prioritizing performance measurement for emergency department care: consensus*  
925 *on evidence-based quality of care indicators.* Cjem, 2011. **13**(5): p. 300-9, E28-43.
- 926 19. Kulstad, E.B., et al., *ED overcrowding is associated with an increased frequency of medication errors.*  
927 *Am J Emerg Med, 2010. 28*(3): p. 304-9.
- 928 20. Liu, S.W., et al., *A pilot study examining undesirable events among emergency department-boarded*  
929 *patients awaiting inpatient beds.* Ann Emerg Med, 2009. **54**(3): p. 381-5.
- 930 21. Louis Simonet, M., et al., *A predictive score to identify hospitalized patients' risk of discharge to a post-*  
931 *acute care facility.* BMC Health Serv Res, 2008. **8**: p. 154.
- 932 22. Fox, M.T., et al., *Effectiveness of early discharge planning in acutely ill or injured hospitalized older*  
933 *adults: a systematic review and meta-analysis.* BMC Geriatr, 2013. **13**: p. 70.
- 934 23. McMartin, K., *Discharge planning in chronic conditions: an evidence-based analysis.* Ont Health  
935 *Technol Assess Ser, 2013. 13*(4): p. 1-72.
- 936 24. Fox, M., *Nurse-led early discharge planning for chronic disease reduces hospital readmission rates and*  
937 *all-cause mortality.* Evid Based Nurs, 2016. **19**(2): p. 62.
- 938 25. Kripalani, S., et al., *Effect of a pharmacist intervention on clinically important medication errors after*  
939 *hospital discharge: a randomized trial.* Ann Intern Med, 2012. **157**(1): p. 1-10.
- 940 26. Kripalani, S., et al., *Deficits in communication and information transfer between hospital-based and*  
941 *primary care physicians: implications for patient safety and continuity of care.* JAMA, 2007. **297**(8): p.  
942 831-41.
- 943 27. Coleman, E.A., et al., *Understanding and execution of discharge instructions.* Am J Med Qual, 2013.  
944 **28**(5): p. 383-91.
- 945 28. Verhaegh, K.J., et al., *Transitional care interventions prevent hospital readmissions for adults with*  
946 *chronic illnesses.* Health Aff (Millwood), 2014. **33**(9): p. 1531-9.
- 947 29. Coleman, E.A., et al., *The care transitions intervention: results of a randomized controlled trial.* Arch  
948 *Intern Med, 2006. 166*(17): p. 1822-8.
- 949 30. Naylor, M.D., et al., *Transitional care of older adults hospitalized with heart failure: a randomized,*  
950 *controlled trial.* J Am Geriatr Soc, 2004. **52**(5): p. 675-84.
- 951 31. Buurman, B.M., et al., *Comprehensive Geriatric Assessment and Transitional Care in Acutely*  
952 *Hospitalized Patients: The Transitional Care Bridge Randomized Clinical Trial.* JAMA Intern Med,  
953 2016. **176**(3): p. 302-9.
- 954 32. Jack, B.W., et al., *A reengineered hospital discharge program to decrease rehospitalization: a*  
955 *randomized trial.* Ann Intern Med, 2009. **150**(3): p. 178-87.
- 956 33. Pannick, S., et al., *Effects of Interdisciplinary Team Care Interventions on General Medical Wards: A*  
957 *Systematic Review.* JAMA Intern Med, 2015. **175**(8): p. 1288-98.
- 958 34. Ellis, G., et al., *Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis*  
959 *of randomised controlled trials.* BMJ, 2011. **343**: p. d6553.
- 960 35. Washington, D.I.o.M., *Measuring the Impact on Interprofessional Education on Collaborative Practice*  
961 *and Patient Outcomes.* 2015.
- 962 36. Chambers, D.A., W.G. Feero, and M.J. Khoury, *Convergence of Implementation Science, Precision*  
963 *Medicine, and the Learning Health Care System: A New Model for Biomedical Research.* JAMA, 2016.  
964 **315**(18): p. 1941-2.
- 965 37. Fisher, E.S., S.M. Shortell, and L.A. Savitz, *Implementation Science: A Potential Catalyst for Delivery*  
966 *System Reform.* JAMA, 2016. **315**(4): p. 339-40.
- 967 38. Cassel, C.K., et al., *Getting more performance from performance measurement.* N Engl J Med, 2014.  
968 **371**(23): p. 2145-7.
- 969 39. Higgins, A., G. Veselovskiy, and L. McKown, *Provider performance measures in private and public*  
970 *programs: achieving meaningful alignment with flexibility to innovate.* Health Aff (Millwood), 2013.  
971 **32**(8): p. 1453-61.
- 972 40. Meyer, G.S., et al., *More quality measures versus measuring what matters: a call for balance and*  
973 *parsimony.* BMJ Qual Saf, 2012. **21**(11): p. 964-8.
- 974 41. Jha, A.K., E.J. Orav, and A.M. Epstein, *Public reporting of discharge planning and rates of readmissions.*  
975 *N Engl J Med, 2009. 361*(27): p. 2637-45.
- 976 42. Moore, L., et al., *Derivation and Validation of a Quality Indicator to Benchmark In-Hospital*  
977 *Complications Among Injury Admissions.* JAMA Surg, 2016.
- 978 43. Taichman, D.B., et al., *Sharing Clinical Trial Data--A Proposal from the International Committee of*  
979 *Medical Journal Editors.* N Engl J Med, 2016. **374**(4): p. 384-6.
- 980 44. Bierer, B.E., et al., *A Global, Neutral Platform for Sharing Trial Data.* N Engl J Med, 2016.
- 981 45. Merson, L., O. Gaye, and P.J. Guerin, *Avoiding Data Dumpsters - Toward Equitable and Useful Data*  
982 *Sharing.* N Engl J Med, 2016.
- 983 46. **Schuetz, P., et al., Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic**  
984 **use in lower respiratory tract infections: the ProHOSP randomized controlled trial.** JAMA, 2009.  
985 **302**(10): p. 1059-66.
- 986 47. **Schuetz, P., et al., Quality of care delivered by fee-for-service and DRG hospitals in Switzerland**  
987 **in patients with community-acquired pneumonia.** Swiss Med Wkly, 2011. **141**: p. w13228.

- 988 48. Suter-Widmer, I., et al., *Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study*. BMC Pulm Med, 2012. 12: p. 21.
- 989
- 990 49. Baehni, C., et al., *Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives*. BMC Pulm Med, 2010. 10: p. 12.
- 991
- 992
- 993 50. Faessler, L., et al., *Psychological distress in medical patients seeking ED care for somatic reasons: results of a systematic literature review*. Emerg Med J, 2015.
- 994
- 995 51. Albrich, W.C., et al., *Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial*. Eur Respir J, 2013. 42(4): p. 1064-75.
- 996
- 997 52. Albrich, W.C., et al., *Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm*. BMC Infect Dis, 2011. 11: p. 112.
- 998
- 999
- 1000 53. Conca, A., et al., *OPTIMA - Optimierter Patienten-Transfer durch innovatives multidisziplinäres Assessment - Projektbeschreibung der Phase I*. Zeitschrift für Pflegewissenschaft 2012:291-298, 2012: p. 291-298.
- 1001
- 1002
- 1003 54. Katan, M., et al., *Stress hormones predict cerebrovascular re-events after transient ischemic attacks*. Neurology, 2011. 76(6): p. 563-6.
- 1004
- 1005 55. Dusemund, F., et al., *Multidisciplinary Assessment to Personalize Length of Stay in Acute Decompensated Heart Failure (OPTIMA II ADHF)*. J Clin Med Res, 2012. 4(6): p. 402-9.
- 1006
- 1007 56. Birsen Arici, M.M., Philipp Schuetz, Beat Mueller, Werner C. Albrich, *Potential Role of Biomarkers in the Management of Syncope*. International Journal of Clinical Medicine, 2012(3): p. 744-750.
- 1008
- 1009
- 1010 57. Drozdov, D., et al., *Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections--'triple p in uti': study protocol for a randomized controlled trial*. Trials, 2013. 14: p. 84.
- 1011
- 1012
- 1013 58. Drozdov, D., et al., *Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial*. BMC Med, 2015. 13: p. 104.
- 1014
- 1015 59. Karakoumis, J., et al., *Emergency Presentations With Nonspecific Complaints-the Burden of Morbidity and the Spectrum of Underlying Disease: Nonspecific Complaints and Underlying Disease*. Medicine (Baltimore), 2015. 94(26): p. e840.
- 1016
- 1017 60. Conca, A., et al., *[At admission planning discharge already]*. Krankenpflege. Soins infirmiers, 2013. 106(1): p. 20-3.
- 1018
- 1019
- 1020 61. Conca, A., et al., *Erfassung eines Nachakutpflegebedarf bei hospitalisierten, medizinischen Patienten durch die „Post-Acute Care Discharge scores“ (PACD)*. Pflegewissenschaft, 2015. 11/15, 17. Jahrgang.
- 1021
- 1022
- 1023 62. Griffiths, P. and J. Wilson-Barnett, *The effectiveness of 'nursing beds': a review of the literature*. J Adv Nurs, 1998. 27(6): p. 1184-92.
- 1024
- 1025 63. Griffiths, P.D., et al., *Effectiveness of intermediate care in nursing-led in-patient units*. Cochrane Database Syst Rev, 2007(2): p. CD002214.
- 1026
- 1027 64. Brunner, C., et al., *Patienten und pflegende Angehörige im Fokus von Nurse-led care*. Krankenpflege, 2015. 1: p. 14-17.
- 1028
- 1029 65. Griffiths, P., et al., *Post-acute intermediate care in nursing-led units: a systematic review of effectiveness*. Int J Nurs Stud, 2005. 42(1): p. 107-16.
- 1030
- 1031 66. Harris, R., et al., *Economic evaluation of a nursing-led inpatient unit: the impact of findings on management decisions of service utility and sustainability*. J Nurs Manag, 2005. 13(5): p. 428-38.
- 1032
- 1033 67. Schuetz, P., et al., *Optimizing triage and hospitalization in adult general medical emergency patients: the triage project*. BMC Emerg Med, 2013. 13: p. 12.
- 1034
- 1035 68. Paasche-Orlow, M.K., et al., *Tailored education may reduce health literacy disparities in asthma self-management*. Am J Respir Crit Care Med, 2005. 172(8): p. 980-6.
- 1036
- 1037 69. Blum, C.A., et al., *Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial*. Lancet, 2015. 385(9977): p. 1511-8.
- 1038
- 1039 70. Schuetz, P., et al., *Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study*. Crit Care, 2015. 19(1): p. 377.
- 1040
- 1041
- 1042 71. Christ, M., et al., *Modern triage in the emergency department*. Deutsches Arzteblatt international, 2010. 107(50): p. 892-8.
- 1043
- 1044 72. Steiner, D., et al., *Performance of the Manchester Triage System in Adult Medical Emergency Patients: A Prospective Cohort Study*. J Emerg Med, 2015.
- 1045
- 1046 73. Kutz, A., et al., *Predictors for Delayed Emergency Department Care in Medical Patients with Acute Infections - An International Prospective Observational Study*. PLoS One, 2016. 11(5): p. e0155363.
- 1047
- 1048
- 1049
- 1050 74. Felder, S., et al., *Association of nutritional risk and adverse medical outcomes across different medical inpatient populations*. Nutrition, 2015. 31(11-12): p. 1385-93.
- 1051
- 1052 75. Rast, A.C., et al., *Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study*. Dis Markers, 2015. 2015: p. 795801.
- 1053

- 1054 76. Graedel, L., et al., **Vitamin D Deficiency Strongly Predicts Adverse Medical Outcome Across**  
1055 **Different Medical Inpatient Populations: Results From a Prospective Study.** *Medicine*  
1056 **(Baltimore), 2016. 95(19): p. e3533.**
- 1057 77. Panzer, R.J., et al., *Increasing demands for quality measurement.* *JAMA*, 2013. **310(18): p. 1971-80.**
- 1058 78. Jumbe, N.L., J.C. Murray, and S. Kern, *Data Sharing and Inductive Learning - Toward Healthy Birth,*  
1059 *Growth, and Development.* *N Engl J Med*, 2016.
- 1060 79. Baker, R., et al., *Tailored interventions to overcome identified barriers to change: effects on*  
1061 *professional practice and health care outcomes.* *Cochrane Database Syst Rev*, 2010(3): p. CD005470.
- 1062 80. 14 - Internationale Klassifikation der Krankheiten (ICD-10).  
1063 [http://www.bfs.admin.ch/bfs/portal/de/index/infothek/nomenklaturen/blank/blank/cim10/02/05.](http://www.bfs.admin.ch/bfs/portal/de/index/infothek/nomenklaturen/blank/blank/cim10/02/05.html)  
1064 [html](http://www.bfs.admin.ch/bfs/portal/de/index/infothek/nomenklaturen/blank/blank/cim10/02/05.html). Accessed 27.05.2016. Bundesamt für Statistik: Neuchâtel, 2014.
- 1065 81. Elixhauser, A., et al., *Comorbidity measures for use with administrative data.* *Med Care*, 1998. **36(1):**  
1066 **p. 8-27.**
- 1067 82. Zuckerman, R.B., et al., *Readmissions, Observation, and the Hospital Readmissions Reduction Program.*  
1068 *N Engl J Med*, 2016. **374(16): p. 1543-51.**
- 1069 83. Penfold, R.B. and F. Zhang, *Use of interrupted time series analysis in evaluating health care quality*  
1070 *improvements.* *Acad Pediatr*, 2013. **13(6 Suppl): p. S38-44.**
- 1071 84. Powell, B.J., et al., *A compilation of strategies for implementing clinical innovations in health and*  
1072 *mental health.* *Med Care Res Rev*, 2012. **69(2): p. 123-57.**
- 1073 85. Fiore, L.D. and P.W. Lavori, *Integrating Randomized Comparative Effectiveness Research with Patient*  
1074 *Care.* *N Engl J Med*, 2016. **374(22): p. 2152-8.**
- 1075 86. Albrich, W.C., et al., **Biomarker-enhanced triage in respiratory infections - a proof-of-concept**  
1076 **feasibility trial.** *Eur Respir J*, 2013.
- 1077 87. Briel, M., et al., **Procalcitonin-guided antibiotic use vs a standard approach for acute**  
1078 **respiratory tract infections in primary care.** *Arch Intern Med*, 2008. **168(18): p. 2000-7;**  
1079 **discussion 2007-8.**
- 1080 88. Leuppi, J.D., et al., **Short-term vs conventional glucocorticoid therapy in acute exacerbations of**  
1081 **chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.** *JAMA*, 2013.  
1082 **309(21): p. 2223-31.**
- 1083 89. Thomann, R., et al., **Evaluation of an algorithm for intensive subcutaneous insulin therapy in**  
1084 **noncritically ill hospitalised patients with hyperglycaemia in a randomised controlled trial.**  
1085 *Swiss Med Wkly*, 2013. **143: p. w13808.**
- 1086 90. Schuetz, P., et al., **Procalcitonin to guide initiation and duration of antibiotic treatment in acute**  
1087 **respiratory infections: an individual patient data meta-analysis.** *Clin Infect Dis*, 2012. **55(5):**  
1088 **p. 651-62.**
- 1089 91. Dellinger, R.P., et al., *Surviving sepsis campaign: international guidelines for management of severe*  
1090 *sepsis and septic shock: 2012.* *Crit Care Med*, 2013. **41(2): p. 580-637.**
- 1091 92. Woodhead, M., et al., *Guidelines for the management of adult lower respiratory tract infections.* *Clin*  
1092 *Microbiol Infect*, 2011. **17(Suppl. 6): E1-E59.**
- 1093 93. Schuetz P, B.N., German S, Baumgartner A, Mueller B, **Incorporation of Nutritional Factors and**  
1094 **Insulin Resistance into Insulin Sliding Scales in the Non-Critical Care Inpatient Setting: A**  
1095 **"Before/After" Study.** *J Diabetes Metab*, 2014. **5(1).**
- 1096 94. Wensing, M., M. Bosch, and R. Gröl, *Developing and selecting interventions for translating knowledge*  
1097 *to action.* *Cmaj*, 2010. **182(2): p. E85-8.**
- 1098 95. Damschroder, L.J., et al., *Fostering implementation of health services research findings into practice: a*  
1099 *consolidated framework for advancing implementation science.* *Implement Sci*, 2009. **4: p. 50.**
- 1100 96. Milstein, A. and S. Shortell, *Innovations in care delivery to slow growth of US health spending.* *JAMA*,  
1101 2012. **308(14): p. 1439-40.**
- 1102 97. Craig, P., et al., *Developing and evaluating complex interventions: the new Medical Research Council*  
1103 *guidance.* *BMJ*, 2008. **337: p. a1655.**
- 1104 98. *Schweizerische Arbeitskräfteerhebung (SAKE): Modul Unbezahlte Arbeit und Schweizerische*  
1105 *Lohnstrukturhebung (LSE).* Accessed 27.06.2016., 2013, Bundesamt für Statistik: Neuchâtel.
- 1106 99. *Statistisches Lexikon der Schweiz: Durchschnittliche Lebensdauer in Jahren.* Accessed 29.06.2016., 2016,  
1107 Bundesamt für Statistik: Neuchâtel.
- 1108 100. Céline Schmid Botkine, K.B., Ewa Kasprzycki, Fabienne Rausa, *Demos Newsletter: Korrigierte Version*  
1109 *vom 21.7.2010.* Bundesamt für Statistik, 2010(Nr. 1): p. 1-15.
- 1110 101. *Kosten und Finanzierung des Gesundheitswesens 2014: Provisorische Zahlen: Medienmitteilung.*  
1111 *Accessed 28.06.2016., 2016, Bundesamt für Statistik: Neuchâtel.*
- 1112 102. *Statistiken der stationären Gesundheitsversorgung 2011: Provisorische Zahlen: 2011 behandelten*  
1113 *Schweizer Spitäler 36'853 Personen pro Tag.* Accessed 27.06.2016., 2012, Bundesamt für Statistik:  
1114 Neuchâtel.  
1115  
1116